X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Efesa (efepoetin alfa) is a bio-better drug for CKD-induced anemia, developed based on hyFc®, Genexine's proprietary long-acting platform technology, which is investigated for the treatment of chronic kidney disease induced anemia in non-dialysis patients.
Lead Product(s): Efepoetin Alfa
Therapeutic Area: Nephrology Product Name: Efesa
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Genexine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Details:
Under the terms of the agreement, Henlius will be responsible for development and commercialisation of Hansizhuang (serplulimab injection) as a treatment for two indications including ES-SCLC, Henlius' novel anti-PD-1 mAb, in 12 MENA countries.
Lead Product(s): Serplulimab
Therapeutic Area: Oncology Product Name: Hansizhuang
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Shanghai Henlius Biotech
Deal Size: $665.0 million Upfront Cash: $7.0 million
Deal Type: Licensing Agreement September 12, 2023
Details:
Through this licensing agreement, KGBio and Genexine aim to develop a and commercialize an immuno-oncology drug GX-I7 (Efineptakin Alpha), namely long-acting interleukin-7 which uses the Genexine hyFc technology platform.
Lead Product(s): Efineptakin alfa
Therapeutic Area: Oncology Product Name: GX-I7
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Genexine
Deal Size: $1,100.0 million Upfront Cash: $27.0 million
Deal Type: Licensing Agreement February 18, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
